Comment and reply on: Pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimens

Author： Santini Daniele Frezza Anna Maria Venditti Olga Intagliata Salvatore dell'Aquila Emanuela Guida Francesco Vincenzi Bruno Tonini Giuseppe

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.17, Iss.4, 2013-04, pp. : 473-475

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Multidrug regimens cost effective in prevention of CVD

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 510, 2006-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Agents under investigation for the treatment and prevention of neutropenia

By Huston Alissa Lyman Gary H

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 11, 2007-11 ,pp. : 1831-1840

Informa Healthcare

Access to resources Recommend Favorite

Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia

By Rofail Pierre Tadros Mariam Ywakim Riham Tadrous Mina Krug Allison Cosler Leon E

Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 12, Iss. 6, 2012-12 ,pp. : 699-709

Informa Healthcare

Access to resources Recommend Favorite

Pegfilgrastim superior to filgrastim for preventing febrile neutropenia

Inpharma, Vol. 1, Iss. 1606, 2007-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Pegfilgrastim fits the bill for febrile neutropenia prophylaxis in Europe

Inpharma, Vol. 1, Iss. 1566, 2006-01 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite